Charles River Laboratories International (CRL) Receivables (2009 - 2026)

Charles River Laboratories International has reported Receivables for 18 years, with the latest figure at $720.5 million in Q2 2026.

• On a quarterly basis, Receivables fell 7.68% year-over-year to $720.5 million in Q2 2026; TTM through Jun 2026 was $720.5 million, a 7.68% decrease from a year earlier, with the FY2025 full-year figure at $719.3 million, down 2.69% from the prior year.
• Receivables was $720.5 million for Q2 2026 at Charles River Laboratories International, up from $708.4 million in the prior quarter.
• The five-year high for Receivables was $820.5 million in Q3 2023, with the low at $708.4 million in Q1 2026.
• Average Receivables over 5 years is $769.2 million, with a median of $775.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Receivables gained 18.11% in 2022, then dropped 8.35% in 2026.
• Over 5 years, Receivables stood at $763.7 million in 2022, then rose by 5.56% to $806.1 million in 2023, then retreated by 8.3% to $739.2 million in 2024, then declined by 2.69% to $719.3 million in 2025, then rose by 0.16% to $720.5 million in 2026.
• The last three Receivables figures came in at $720.5 million (Q2 2026), $708.4 million (Q1 2026), and $719.3 million (Q4 2025), per Business Quant data.